Background/Aim: Nitric oxide is a potent regulator of intrarenal hemodynamics and may influence the renal function. We investigated whether polymorphism of intron 4 of the endothelial constitutive nitric oxide synthase (ecNOS) gene is related to the progression of chronic renal failure. Methods: Polymorphism of ecNOS intron 4 was studied in 1,005 hemodialysis patients (710 with nondiabetic nephropathy and 295 with diabetic nephropathy) and was compared with the findings in 189 healthy subjects. ecNOS genotypes were determined by the polymerase chain reaction, followed by agarose gel electrophoresis. Results: The frequencies of ecNOS4a/a, ecNOS4a/b, and ecNOS4b/b genotypes were, respectively, 0% (0/189), 13.8% (26/189), and 86.2% (163/189) in the control group; 1.7% (12/710), 22.1% (157/710), and 76.2% (541/710) in the nondiabetic nephropathy group, and 1.0% (3/295), 22.7% (67/295), and 76.3% (225/295) in the diabetic nephropathy group. The frequency of ecNOS4a (ecNOSa/a and ecNOSa/b) was significantly higher in both the nondiabetic group and in the diabetic group than in the controls (p = 0.0025 and p = 0.0438, respectively). Conclusion: There was a significantly higher frequency of the a allele of intron 4 in both nondiabetic and diabetic hemodialysis patients, so the polymorphism of intron 4 of the ecNOS gene may have a wide influence on the progression of renal disease.

Keywords:
Endothelial nitric oxide synthase, Gene polymorphism, End-stage renal disease, Diabetic nephropathy, Nondiabetic nephropathy
1.
Schmidt HHHW, Walter U: NO at work. Cell 1994;78:919–925.
2.
Nadaud S, Bonnardeaux A, Lathrop M, Soubrier F: Gene structure polymorphism and mapping of the human endothelial nitric oxide synthase gene. Biochem Biophys Res Commun 1994;198:1027–1033.
3.
Marsden PA, Heng HHQ, Scherer SW, Stewart RJ, Hall AV, Shi X-M, Tsui L-C, Schappert KT: Structure and chromosomal localization of the human constitutive endothelial nitric oxide synthase gene. J Biol Chem 1993;268:17478–17488.
4.
Miyahara K, Kawamoto T, Sase K, Yui Y, Toda K, Yang LX, Hattori R, Aoyama T, Yamamoto Y, Doi Y, Ogoshi S, Hashimoto K, Kawai C, Sasayama S, Shizuta Y: Cloning and structural characterization of the human endothelial nitric-oxide-synthase gene. Eur J Biochem 1994;223:719–726.
5.
Wang XL, Sim AS, Badenhop RF, McCredie RM, Wilcken DE: A smoking-dependent risk of coronary artery disease associated with a polymorphism of the endothelial nitric oxide synthase gene. Nat Med 1996;2:41–45.
6.
Zate R, De Nucci G: Effects of acute nitric oxide inhibition on rat glomerular microcirculation. Am J Physiol 1991;261:F360–F363.
7.
Tolins JP, Palmer RMJ, Moncada S, Raij L: Role of endothelium-derived relaxing factor in regulation of renal hemodynamic responses. Am J Physiol 1990;258:H655–H662.
8.
Bredt DS, Snyder SH: Isolation of nitric oxide synthase, a calmodulin-requiring enzyme. Proc Natl Acad Sci USA 1990;87:682–685.
9.
Baylis C, Mitruka B, Deng A: Chronic blockade of nitric oxide synthesis in the rat produces systemic hypertension and glomerular damage. J Clin Invest 1992;90:278–281.
10.
Yokoyama K, Tsukada T, Matsuoka H, Hara S, Yamada A, Kawaguchi Y: High accumulation of endothelial nitric oxide synthase (ecNOS): A gene polymorphism in patients with end-stage renal disease. Nephron 1998;79:360–361.
11.
Wang Y, Kikuchi S, Suzuki H, Nagase S, Koyama A: Endothelial nitric oxide synthase gene polymorphism in intron 4 affects the progression of renal failure in non-diabetic renal diseases. Nephrol Dial Transplant 1999;14:2898–2902.
12.
Node K, Kitakaze M, Yoshikawa H, Kosaka H, Hori M: Reduced plasma concentrations of nitrogen oxide in individuals with essential hypertension. Hypertension 1997;30:405–408.
13.
Huang PL, Huang Z, Mashimo H, Block KD, Moskowitz MA, Bevan JA, Fishman MC: Hypertension in mice lacking the gene for endothelial nitric oxide synthase. Nature 1995;377:239–242.
14.
Gardiner SM, Compton AM, Bennett T, Palmer RMJ, Moncada S: Control of regional blood flow by endothelium-derived nitric oxide. Hypertension 1990;15:486–492.
15.
Yokoyama K, Tsukada T, Nakayama M, Hara S, Yamada A, Kawaguchi Y, Hosoya T: An intron 4 gene polymorphism in endothelial cell nitric oxide synthase might modulate volume-dependent hypertension in patients on hemodialysis. Nephron 2000;85:232–237.
16.
Morita T, Ito H, Suehiro T, Tahara K, Matsumori A, Chikazawa H, Nakauchi Y, Nishiya K, Hashimoto K: Effect of a polymorphism of endothelial nitric oxide synthase gene in Japanese patients with IgA nephropathy. Clin Nephrol 1999;52:203–209.
17.
Wang YX, Brooks DP, Edwards RM: Attenuated glomerular cGMP production and renal vasodilation in streptozotocin-induced diabetic rats. Am J Pyhsiol 1993;264:R952–R956.
18.
Trachtman H, Futterweit S, Singhal P: Nitric oxide modulates the synthesis of extracellular matrix proteins in cultured rat mesangial cells. Biochem Biophys Res Commun 1995;207:120–125.
19.
Trachtman H, Futterweit S, Grag P, Reddy K, Singhal PC: Nitric oxide stimulates the activity of a 72-kDa neutral matrix metalloproteinase in cultured rat mesangial cells. Biochem Biophys Res Commun 1996;218:704–708.
20.
Trachtman H, Futterweit S, Crimmins DL: High glucose inhibits nitric oxide production in cultured rat mesangial cells. J Am Soc Nephrol 1997;8:1276–1282.
© 2001 S. Karger AG, Basel
2001
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.